Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Monday, November 10, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented late-breaking data on PBGENE-HBV at AASLD, highlighting its safety and tolerability. The gene editing therapy showed cumulative, dose-dependent antiviral activity in the first three cohorts, indicating promising results in treating chronic Hepatitis B. This presentation marks a significant advancement in HBV treatment options.
Price reaction · baseline $6.07 (2025-11-10 close) · hit after-hours · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
-1.2%
Market Sentiment Analysis
POSITIVE FACTORS
PBGENE-HBV demonstrated safety and tolerability.
Cumulative, dose-dependent antiviral activity was observed.
The therapy targets HBV cccDNA effectively.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at 5:45pm EST on Monday, November 10, 2025 PBGENE-HBV was well-tolerated across
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is a gene editing therapy designed to treat chronic Hepatitis B.
What were the results presented at AASLD?
The results highlighted PBGENE-HBV's safety, tolerability, and antiviral activity.
What does PBGENE-HBV target?
It targets HBV cccDNA and integrated HBV DNA directly.
When was the presentation at AASLD?
The presentation took place on November 10, 2025, at 5:45pm EST.